Britanin Exhibits Potential Inhibitory Activity on Human Prostate Cancer Cell Lines Through PI3K/Akt/NF-κB Signaling...

Area of Science:

• Natural Products Chemistry
• Cancer Biology
• Immunology

Background:

• Britanin, a sesquiterpene lactone, possesses known antioxidant and anti-inflammatory properties.
• Its tumor inhibitory activity and underlying mechanisms, particularly in prostate cancer, remain largely unexplored.

Purpose of the Study:

• To investigate the efficacy of britanin against human prostate cancer cells both in vitro and in vivo.
• To elucidate the molecular mechanisms underlying britanin's anti-cancer effects, including its impact on cell signaling pathways and immune activation.

Main Methods:

• In vitro studies using human prostate cancer cell lines (PC-3, PC-3-LUC, DU-145) to assess proliferation, migration, and motility.
• In vivo studies utilizing a luciferase-labeled PC-3-LUC tumor xenograft mouse model with bioluminescence imaging.
• Analysis of protein expression levels, including PI3K/Akt, NF-κB pathway components, and apoptosis-related proteins (Bax).
• Measurement of interleukin-2 levels to assess immune response.

Main Results:

• Britanin significantly inhibited prostate cancer cell proliferation, migration, and motility in vitro.
• In vivo, britanin demonstrated tumor growth inhibition in the PC-3-LUC xenograft model.
• Britanin upregulated interleukin-2, indicating enhanced antitumor immune activation.
• Downregulation of PI3K/Akt and NF-κB signaling pathway proteins and upregulation of Bax were observed.

Conclusions:

• Britanin exhibits significant in vitro and in vivo anti-prostate cancer activity.
• The anti-cancer effects are mediated through the regulation of PI3K/Akt/NF-κB pathways and immune system activation.
• Britanin represents a potential therapeutic agent for prostate cancer treatment.